BEOVU (brolucizumab) is a prescription medication used in the treatment of neovascular (wet) age-related macular degeneration (AMD), a chronic eye disorder that results in loss of vision in the center of the visual field due to damage to the retina. It belongs to a class of drugs known as anti-VEGF (vascular endothelial growth factor) agents, which work by inhibiting the growth of abnormal blood vessels in the eye that can leak fluid and cause vision loss associated with wet AMD. BEOVU is administered through injections directly into the eye by a healthcare professional, typically at scheduled intervals determined by a doctor based on the patient's condition. Its approval offers an additional treatment option for individuals suffering from wet AMD, aiming to improve vision or prevent further deterioration.
When using Beovu (brolucizumab), it is crucial to adhere strictly to your doctor's instructions and thoroughly read the label that accompanies the medication. Beovu is used to treat neovascular (wet) age-related macular degeneration (AMD) and can have side effects that may impact your daily activities. Common side effects include redness and pain at the injection site, blurred vision, and floaters. Although rare, more serious side effects like retinal detachment and endophthalmitis, an infection inside the eye, can occur. It's essential to report any unusual symptoms to your doctor immediately. There are no specific warnings against driving after receiving Beovu; however, any vision changes experienced after treatment may temporarily affect your ability to drive or operate machinery safely. Always inform your doctor about all other medications you are taking, as interactions can affect the efficacy and safety of Beovu. Following these precautions can help ensure the best possible outcome with your treatment.